Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the colorectal cancer drugs market right now?

In past years, the market size of drugs treating colorectal cancer has seen a significant surge. It is projected to escalate from $20.71 billion in 2024 to $21.98 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The growth seen in the historical period is credited to the confluence of multiple approaches, the advent of chemotherapy, improvements in surgical methods, the rise of targeted therapies, along with clinical trials and extensive research.

How fast Is the colorectal cancer drugs market expected to grow, and what’s its future value?

It is anticipated that the thermal transfer label market will experience robust growth in the forthcoming years. The market size is projected to expand to $4.93 billion by 2029, with an expected compound annual growth rate (CAGR) of 9.6%. Several factors contributing to this growth during the forecast period include the expansion of global supply chains, the adoption of eco-friendly labeling solutions, pharmaceutical serialization, the rise of online retail, and the emergence of smart packaging trends. The forecast period is also likely to witness several significant trends such as the rise in customization and personalization, challenges in global supply chain, the incorporation of RFID technology, market consolidation, and digital transformations.

Get your colorectal cancer drugs market report here!

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

What are the leading drivers of growth in the colorectal cancer drugs market?

The colorectal cancer drugs market is projected to expand owing to the rising preference for personalized medicines. Personalized medicine, also referred to as precision medicine, is a healthcare and medical treatment approach that takes into consideration patients’ unique gene variations, living environments, and lifestyles. This tailor-made way of treating colorectal cancer is revolutionizing patient care, promising more targeted and effective treatments. As the research and development of new drugs become more inclined towards particular genetic and molecular profiles, it will potentially fuel the growth of the colorectal cancer drugs market. For instance, in February 2024, as per the US-based non-profit organization, the Personalized Medicine Coalition, in 2023, the FDA gave the green light to 16 new tailor-made treatments for patients suffering from rare diseases. This was a remarkable rise from the six approvals handed out in 2022. As a result, the growth of the colorectal cancer drugs market is being steered by the escalating demand for personalized medicine.

What are the key segments defining the colorectal cancer drugs market?

The colorectal cancer drugs market covered in this report is segmented –

1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, BRAF Or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators

2) By Class: Immunotherapy, Chemotherapy, Other Classes

3) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab, Ramucirumab, Other VEGF Inhibitors

2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab, Panitumumab, Other EGFR Inhibitors

3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab, Nivolumab, Other PD1 Or PDL1 Inhibitors

4) By BRAF Or MEK Inhibitors: Vemurafenib, Encorafenib, Trametinib, Other BRAF Or MEK Inhibitors

5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib, Sorafenib, Other TKI Inhibitors

6) By Immunomodulators: Checkpoint Inhibitors, Other Immunomodulating Agents

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2590&type=smp

Who are the key players steering the development of the colorectal cancer drugs market?

Major companies operating in the colorectal cancer drugs market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Taiho Oncology Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.

What emerging trends are influencing the growth of the colorectal cancer drugs market?

The use of targeted therapies is already showing promise in prolonging the lives of patients with metastatic colorectal cancer, compared to those simply undergoing chemotherapy. This approach encompasses a range of treatments, including hormone therapies, gene expression modifiers, apoptosis triggers, inhibitors of angiogenesis, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. The appeal of targeted therapy lies in its ability to target cancer cells exclusively, thus reducing the toxicity to other cells. Opdivo and Keytruda are two examples of such targeted therapies.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2590

Which regions are most influential in expanding the colorectal cancer drugs market?

North America was the largest region in the colorectal cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Drugs For Erectile Dysfunction Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-erectile-dysfunction-global-market-report

Gastrointestinal Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Genito-Urinary Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: